T 2101/15 of 22.08.2019
- European Case Law Identifier
- ECLI:EP:BA:2019:T210115.20190822
- Date of decision
- 22 August 2019
- Case number
- T 2101/15
- Online on
- 10 August 2020
- Petition for review of
- -
- Application number
- 06815305.5
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- FORMULATION COMPRISING METFORMIN AND VILDAGLIPTIN
- Applicant name
- Novartis AG
Novartis Pharma GmbH - Opponent name
- Teva Pharmaceutical Industries Ltd.
Gallafent, Alison
Actavis Group Ptc Ehf
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2) (2007)European Patent Convention Art 56 (2007)
- Keywords
- Amendments - added subject-matter (yes)
Amendments - main request, auxiliary request 1
Inventive step - (yes)
Inventive step - auxiliary request 2 - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent in amended form on the basis of claims 1 to 9 of auxiliary request 2 filed at the oral proceedings before the board, and a description to be adapted thereto.